- Home
- ARWR vs FDS Comparison
ARWR vs FDS Comparison
Compare ARWR & FDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARWR | FDS |
|---|---|---|
| Founded | 2003 | 1978 |
| Country | United States | United States |
| Employees | N/A | 6258 |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 8.3B |
| IPO Year | 2009 | 1996 |
Fundamental Metrics
Financial Performance| Metric | ARWR | FDS |
|---|---|---|
| Price | $73.08 | $246.91 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 11 |
| Target Price | $83.40 | ★ $284.80 |
| AVG Volume (30 Days) | ★ 1.4M | 841.5K |
| Earning Date | 05-07-2026 | 03-31-2026 |
| Dividend Yield | N/A | ★ 1.89% |
| EPS Growth | ★ 99.80 | 11.79 |
| EPS | N/A | ★ 7.65 |
| Revenue | $16,142,321.00 | ★ $1,435,351,000.00 |
| Revenue This Year | N/A | $7.16 |
| Revenue Next Year | N/A | $5.55 |
| P/E Ratio | ★ N/A | $32.21 |
| Revenue Growth | N/A | ★ 6.31 |
| 52 Week Low | $14.30 | $185.00 |
| 52 Week High | $82.26 | $453.41 |
Technical Indicators
Market Signals| Indicator | ARWR | FDS |
|---|---|---|
| Relative Strength Index (RSI) | 47.50 | 56.65 |
| Support Level | $70.19 | $195.87 |
| Resistance Level | $77.39 | $247.33 |
| Average True Range (ATR) | 3.54 | 11.40 |
| MACD | -0.75 | 1.24 |
| Stochastic Oscillator | 34.34 | 55.92 |
Price Performance
Historical ComparisonAbout ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
About FDS FactSet Research Systems Inc.
FactSet provides financial data and portfolio analytics to the global investment community. The company aggregates data from third-party data suppliers, news sources, exchanges, brokerages, and contributors into its workstations. In addition, it provides essential portfolio analytics that companies use to monitor portfolios and address reporting requirements. Buy-side clients (including wealth and corporate clients) account for over 80% of FactSet's annual subscription value. In 2015, the company acquired Portware, a provider of trade execution software. In 2017, it acquired BISAM, a risk management and performance measurement provider. In 2022, it completed its purchase of CUSIP Global Services.